Showing 1 - 5 results of 5 for search 'John Wityak', query time: 0.02s Refine Results
  1. 1
    MR-based spatial normalization improves [18F]MNI-659 PET regional quantification and detectability of disease effect in the Q175 mouse model of Huntington's disease.

    MR-based spatial normalization improves [18F]MNI-659 PET regional quantification and detectability of disease effect in the Q175 mouse model of Huntington's disease. by Daniele Bertoglio, Jeroen Verhaeghe, Lauren Kosten, David Thomae, Annemie Van der Linden, Sigrid Stroobants, John Wityak, Celia Dominguez, Ladislav Mrzljak, Steven Staelens

    Published 2018-01-01
    Get full text
    Article
  2. 2
    Improved synthesis of [18F] fallypride and characterization of a Huntington’s disease mouse model, zQ175DN KI, using longitudinal PET imaging of D2/D3 receptors

    Improved synthesis of [18F] fallypride and characterization of a Huntington’s disease mouse model, zQ175DN KI, using longitudinal PET imaging of D2/D3 receptors by Tuulia Huhtala, Pekka Poutiainen, Jussi Rytkönen, Kimmo Lehtimäki, Teija Parkkari, Iiris Kasanen, Anu J. Airaksinen, Teija Koivula, Patrick Sweeney, Outi Kontkanen, John Wityak, Celia Dominiquez, Larry C. Park

    Published 2019-08-01
    Get full text
    Article
  3. 3
    Noninvasive Relative Quantification of [11C]ABP688 PET Imaging in Mice Versus an Input Function Measured Over an Arteriovenous Shunt

    Noninvasive Relative Quantification of [11C]ABP688 PET Imaging in Mice Versus an Input Function Measured Over an Arteriovenous Shunt by Jeroen Verhaeghe, Daniele Bertoglio, Lauren Kosten, David Thomae, David Thomae, Marleen Verhoye, Annemie Van Der Linden, Leonie Wyffels, Leonie Wyffels, Sigrid Stroobants, Sigrid Stroobants, John Wityak, Celia Dominguez, Ladislav Mrzljak, Steven Staelens

    Published 2018-06-01
    Get full text
    Article
  4. 4
    A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease.

    A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease. by Daniel Todd, Ian Gowers, Simon J Dowler, Michael D Wall, George McAllister, David F Fischer, Sipke Dijkstra, Silvina A Fratantoni, Rhea van de Bospoort, Jessica Veenman-Koepke, Geraldine Flynn, Jamshid Arjomand, Celia Dominguez, Ignacio Munoz-Sanjuan, John Wityak, Jonathan A Bard

    Published 2014-01-01
    Get full text
    Article
  5. 5
    Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates

    Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates by Frank Herrmann, Manuela Hessmann, Sabine Schaertl, Karola Berg-Rosseburg, Christopher J Brown, Galina Bursow, Anass Chiki, Andreas Ebneth, Miriam Gehrmann, Nicole Hoeschen, Madlen Hotze, Stefanie Jahn, Peter D Johnson, Vinod Khetarpal, Alex Kiselyov, Karsten Kottig, Stefanie Ladewig, Hilal Lashuel, Sven Letschert, Matthew R Mills, Kathrin Petersen, Michael E Prime, Christoph Scheich, Gerhard Schmiedel, John Wityak, Longbin Liu, Celia Dominguez, Ignacio Muñoz-Sanjuán, Jonathan A Bard

    Published 2021-09-01
    Get full text
    Article

Search Tools: